Compare TGLS & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | SRPT |
|---|---|---|
| Founded | 1984 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2011 | 2000 |
| Metric | TGLS | SRPT |
|---|---|---|
| Price | $35.99 | $20.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 29 |
| Target Price | ★ $63.33 | $25.85 |
| AVG Volume (30 Days) | 238.3K | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.27 | ★ 2.99 |
| Revenue | $370,984,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $13.56 | N/A |
| Revenue Next Year | $9.04 | N/A |
| P/E Ratio | $30.17 | ★ $6.84 |
| Revenue Growth | ★ 17.98 | 15.58 |
| 52 Week Low | $37.35 | $14.68 |
| 52 Week High | $71.84 | $25.32 |
| Indicator | TGLS | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 33.83 | 54.93 |
| Support Level | N/A | $20.12 |
| Resistance Level | $46.99 | $23.70 |
| Average True Range (ATR) | 1.44 | 1.55 |
| MACD | -0.11 | -0.14 |
| Stochastic Oscillator | 0.88 | 50.28 |
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.